Syndicate content

Archive - Jul 15, 2020

Date

Evox Therapeutics Expands Existing Exosome Patent Portfolio with Further Grant Covering Exosomes for RNA Therapeutics

On July 15, 2020, Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce that the company has been granted a key patent by the United States Patent and Trademark Office (USPTO). This newly issued patent adds to the expanding foundational patent estate held by Evox and further reinforces the company's position within the field of exosome-mediated RNA drug delivery. The recently issued US patent (U.S. Patent 10,704,047) provides broad coverage for pharmaceutical compositions comprising exosomes containing nucleic acid-based therapeutics, such as RNAi agents and antisense oligonucleotides, which have been loaded by electroporation. Per Lundin, PhD, Chief Operating Officer of Evox, commented: "We are very pleased to have been granted another foundational patent, reflecting our scientific and IP leadership in the exosome therapeutics space. This is another significant development that gives Evox dominant coverage in exosome-mediated RNA delivery, as well as key steps in the manufacturing process." Antonin de Fougerolles, PhD, Chief Executive Officer of Evox, added: "Over the past decade, Evox has built an unrivaled global patent estate with broad and deep coverage of the key applications of exosome therapeutics. This recent grant represents a great addition of our IP position and further reinforces Evox's leading position as the partner of choice in the field of exosome therapeutics." Evox Therapeutics is a privately held, Oxford UK-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics.

New Study Illuminates Brain Circuitry Involved In Dysfunctional Social, Repetitive, and Inflexible Behaviors Characteristic of Autism Spectrum Disorders (ASD); Increased Understanding Gives Hope of Perhaps Eventually Treating Aberrant Behaviors in ASD

A team led by University of Texas Southwestern (UTSW) researchers has identified brain circuitry that plays a key role in the dysfunctional social, repetitive, and inflexible behavioral differences that characterize autism spectrum disorders (ASD). The findings, published online on July 13, 2020 in Nature Neuroscience (https://www.nature.com/articles/s41593-020-0665-z), could lead to new therapies for these relatively prevalent disorders. The article is titled “Regulation of Autism-Relevant Behaviors by Cerebellar–Prefrontal Cortical Circuits.” The Centers for Disease Control and Prevention (CDC) estimate that approximately 1 in 54 children in the United States have ASD, a broad range of neurodevelopmental conditions thought to be caused by a combination of genetic and environmental factors. Although researchers have identified some key genes and pathways that contribute to ASD, the underlying biology of these disorders remains poorly understood, says Peter Tsai (https://profiles.utsouthwestern.edu/profile/153860/peter-tsai.html), MD, PhD, Assistant Professor in the Departments of Neurology and Neurotherapeutics, Neuroscience, Pediatrics, and Psychiatry at UTSW Medical Center and a member of the Peter O’Donnell Jr. Brain Institute (https://utswmed.org/odonnell/). However, Dr. Tsai explains, one key brain region that’s been implicated in ASD dysfunction is the cerebellum, part of the hindbrain in vertebrates that holds about three-quarters of all the neurons in the body and has traditionally been linked with motor control. Recent studies by Dr. Tsai and his colleagues have demonstrated that inhibiting activity in a region of the cerebellum known as Rcrus1 can cause altered social and repetitive/inflexible behaviors reminiscent of ASD in mice.

International Society for Extracellular Vesicles (ISEV) 2020 Virtual Annual Meeting, Including Exosomes, July 20-22: Plenary Speakers, Panel Sessions, Featured Abstracts, Oral Abstracts, Poster Chats, & Educational Sessions; FOCUS: 19 MEETING SPONSORS

The International Society for ExtracellularVesicles (ISEV) AnnualMeeting (ISEV2020), Including Exosomes, Is Now VIRTUAL (July 20-22); and will feature over 600 Discussions (Plenary Addresses, Panel Sessions, Featured Abstracts, Oral Abstract Talks, Poster Chats, & Education Sessions). The program can viewed here (https://www.isev.org/mpage/2020Program) and registration can be done here (https://www.isev.org/mpage/2020Registration). As Philip Askenase, MD, eminent Yale Medical School Professor and 30-Year Chief of Allergy & Immunology there, has said, “Exosomes are a sensational biological discovery and they seem to be involved in nearly all biological and clinical processes.” This year’s ISEV annual virtual meeting is being sponsored by a total of 19 companies (https://www.isev.org/mpage/2020Sponsorship) that are keenly interested in the potential of EVs for a wide variety of applications. A list of the ISEV 2020 sponsoring companies, including links to each company’s web site is provided below. Please note that BioQuick News, which will be covering the ISEV 2020 virtual annual meeting, is one of the Bronze Sponsors of this important meeting. PLATINUM SPONSORS: FujiFilm (https://www.fujifilm.com/), Izon (https://izon.com/), NanoFCM (https://www.nanofcm.com/), NanoView Biosciences (https://www.nanoviewbio.com/), Particle Metrix (https://www.particle-metrix.de/en/particle-metrix), and RoosterBio (https://www.roosterbio.com/). GOLD SPONSORS: Beckman Coulter (https://www.beckman.com/), Luminex (https://www.luminexcorp.com/), Malvern Panalytical (https://www.malvernpanalytical.com/en/), Myriade (http://www.myriadelab.com/en/), and Streck (https://www.streck.com/).

BRCA2: An Unexpected Role for This Tumor Suppressor Gene Discovered; Mutations in BRCA2 Impair Alignment of Chromosomes at the Metaphase Plate & May Be Associated with Chromosome Number Aberrations Often Seen in BRCA2-Related Cancers

The BRCA2 protein, produced by the expression of the tumor suppressor gene BRCA2, plays an important role in DNA repair by homologous recombination, which takes place at early phases of the cell cycle. A team from Institut Curie, in collaboration with a group of CEA, revealed an additional role of BRCA2 in the alignment of chromosomes during mitosis (cell division), with significant consequences on chromosome stability. Published in Nature Communications, these results could explain certain chromosomal aberrations observed in BRCA2-mutated tumors. The “Genome Instability and Cancer Predisposition” Team (https://science.institut-curie.org/research/biology-chemistry-of-radiati...) led by Aura Carreira (photo), PhD, in the “Genome integrity, RNA and Cancer” Unit (CNRS/Paris-Saclay University/Institut Curie) is working on the role of BRCA2 in maintaining genome integrity. It was already known that BRCA2 operates in DNA repair by homologous recombination, the DNA duplication phase of the cell cycle. In addition, it was also known that a mutation in the BRCA2 gene predisposes to breast and ovarian cancer. In collaboration with the group of Sophie Zinn-Justin, PhD, at the CEA, Dr. Carreira’s team found an additional and unexpected role of BRCA2 in mitosis, which seems uncoupled to its function in DNA repair. Using a combination of biophysics, biochemistry, cell biology, and genetics tools, these researchers showed that the alignment of chromosomes at the metaphase plate depends on the phosphorylation of BRCA2 by the protein kinase PLK1 (polo-like kinase 1). Importantly, they found that certain BRCA2 variants identified in breast cancer patients were associated with this function during mitosis being altered.